NO843274L - Fremgangsmaate for fremstilling av et immunomodulatormedikament - Google Patents
Fremgangsmaate for fremstilling av et immunomodulatormedikamentInfo
- Publication number
- NO843274L NO843274L NO843274A NO843274A NO843274L NO 843274 L NO843274 L NO 843274L NO 843274 A NO843274 A NO 843274A NO 843274 A NO843274 A NO 843274A NO 843274 L NO843274 L NO 843274L
- Authority
- NO
- Norway
- Prior art keywords
- bacteria
- lysis
- preparation
- active principle
- products
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 33
- 238000000034 method Methods 0.000 title description 14
- 229940121354 immunomodulator Drugs 0.000 title description 2
- 230000002584 immunomodulator Effects 0.000 title description 2
- 241000894006 Bacteria Species 0.000 claims abstract description 60
- 230000009089 cytolysis Effects 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000000047 product Substances 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 10
- 241000588724 Escherichia coli Species 0.000 claims abstract description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 238000011161 development Methods 0.000 claims description 12
- 230000018109 developmental process Effects 0.000 claims description 12
- 241000588722 Escherichia Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000003698 anagen phase Effects 0.000 claims description 9
- 239000002054 inoculum Substances 0.000 claims description 9
- 241001515965 unidentified phage Species 0.000 claims description 9
- 238000011081 inoculation Methods 0.000 claims description 7
- 241000588748 Klebsiella Species 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002927 anti-mitotic effect Effects 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000002141 anti-parasite Effects 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 229940124622 immune-modulator drug Drugs 0.000 claims 3
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 238000011861 anti-inflammatory therapy Methods 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000009109 curative therapy Methods 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000009117 preventive therapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 11
- 208000015181 infectious disease Diseases 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- ZGJHIFYEQJEUKA-UHFFFAOYSA-N buclosamide Chemical compound CCCCNC(=O)C1=CC=C(Cl)C=C1O ZGJHIFYEQJEUKA-UHFFFAOYSA-N 0.000 description 1
- 229950000430 buclosamide Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8313362A FR2550707B1 (fr) | 1983-08-17 | 1983-08-17 | Medicament immunomodulateur d'origine biologique et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO843274L true NO843274L (no) | 1985-02-18 |
Family
ID=9291646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO843274A NO843274L (no) | 1983-08-17 | 1984-08-16 | Fremgangsmaate for fremstilling av et immunomodulatormedikament |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0139551B1 (cs) |
| JP (1) | JPS6069022A (cs) |
| AT (1) | ATE36240T1 (cs) |
| AU (1) | AU564652B2 (cs) |
| CA (1) | CA1229566A (cs) |
| CS (1) | CS270410B2 (cs) |
| DD (1) | DD232432A5 (cs) |
| DE (1) | DE3473228D1 (cs) |
| DK (1) | DK160807C (cs) |
| ES (1) | ES8602415A1 (cs) |
| FR (1) | FR2550707B1 (cs) |
| HU (1) | HU193217B (cs) |
| IL (1) | IL72589A (cs) |
| IN (1) | IN161616B (cs) |
| MA (1) | MA20203A1 (cs) |
| NO (1) | NO843274L (cs) |
| NZ (1) | NZ209171A (cs) |
| OA (1) | OA07794A (cs) |
| PT (1) | PT79090B (cs) |
| SU (1) | SU1487815A3 (cs) |
| YU (1) | YU143284A (cs) |
| ZA (1) | ZA846151B (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876194A (en) * | 1986-07-22 | 1989-10-24 | Hightech Receptor Ab | Protein L and subfragments thereof, with immunoglobulin binding activity, a process for preparing thereof, reagent kit, pharmaceutical composition and a peptococcus magnus strain |
| FR2620130B1 (fr) * | 1987-09-08 | 1990-01-12 | Lipha | Nouveaux polysaccharides hydrosolubles, leur procede d'obtention, leur application a titre de medicaments et preparation les renfermant |
| IL88480A0 (en) * | 1987-11-27 | 1989-06-30 | Univ Toronto | Proteinaceous compositions |
| WO1997045530A1 (fr) * | 1996-05-27 | 1997-12-04 | UZILOVA, Irina Semenovna, Heiress of UZILOV | Utilisation de souches de streptococcus faecium et composition a base de ces souches |
| AU2003215254A1 (en) * | 2002-02-13 | 2003-09-04 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE758977A (fr) * | 1969-11-17 | 1971-05-17 | Glaxo Lab Ltd | Procede biochimique |
| CH633188A5 (fr) * | 1978-05-26 | 1982-11-30 | Om Laboratoires Sa | Medicament contre des maladies infectieuses des voies respiratoires. |
| CH639852A5 (fr) * | 1979-07-26 | 1983-12-15 | Om Laboratoires Sa | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
| US4322405A (en) * | 1981-04-06 | 1982-03-30 | Laboratoires Om Societe Anonyme | Method for treating rheumatoid arthritis |
-
1983
- 1983-08-17 FR FR8313362A patent/FR2550707B1/fr not_active Expired
-
1984
- 1984-07-31 CA CA000460042A patent/CA1229566A/fr not_active Expired
- 1984-08-03 CS CS845921A patent/CS270410B2/cs unknown
- 1984-08-06 IN IN629/DEL/84A patent/IN161616B/en unknown
- 1984-08-06 IL IL72589A patent/IL72589A/xx unknown
- 1984-08-08 DE DE8484401647T patent/DE3473228D1/de not_active Expired
- 1984-08-08 ZA ZA846151A patent/ZA846151B/xx unknown
- 1984-08-08 AT AT84401647T patent/ATE36240T1/de not_active IP Right Cessation
- 1984-08-08 EP EP84401647A patent/EP0139551B1/fr not_active Expired
- 1984-08-10 NZ NZ209171A patent/NZ209171A/xx unknown
- 1984-08-15 AU AU31938/84A patent/AU564652B2/en not_active Ceased
- 1984-08-16 NO NO843274A patent/NO843274L/no unknown
- 1984-08-16 ES ES535213A patent/ES8602415A1/es not_active Expired
- 1984-08-16 DK DK393884A patent/DK160807C/da not_active IP Right Cessation
- 1984-08-16 HU HU843107A patent/HU193217B/hu not_active IP Right Cessation
- 1984-08-16 PT PT79090A patent/PT79090B/pt not_active IP Right Cessation
- 1984-08-16 SU SU843781693A patent/SU1487815A3/ru active
- 1984-08-16 MA MA20427A patent/MA20203A1/fr unknown
- 1984-08-17 OA OA58368A patent/OA07794A/xx unknown
- 1984-08-17 YU YU01432/84A patent/YU143284A/xx unknown
- 1984-08-17 JP JP59170515A patent/JPS6069022A/ja active Pending
- 1984-08-17 DD DD84266389A patent/DD232432A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK393884A (da) | 1985-02-18 |
| DK393884D0 (da) | 1984-08-16 |
| YU143284A (en) | 1991-02-28 |
| DE3473228D1 (en) | 1988-09-15 |
| FR2550707A1 (fr) | 1985-02-22 |
| AU3193884A (en) | 1985-02-21 |
| FR2550707B1 (fr) | 1986-02-28 |
| IN161616B (cs) | 1988-01-02 |
| DK160807B (da) | 1991-04-22 |
| EP0139551A2 (fr) | 1985-05-02 |
| MA20203A1 (fr) | 1985-04-01 |
| PT79090A (fr) | 1984-09-01 |
| CS592184A2 (en) | 1989-11-14 |
| PT79090B (fr) | 1986-08-14 |
| ES535213A0 (es) | 1985-12-01 |
| DD232432A5 (de) | 1986-01-29 |
| DK160807C (da) | 1991-10-07 |
| EP0139551A3 (en) | 1985-07-10 |
| ES8602415A1 (es) | 1985-12-01 |
| EP0139551B1 (fr) | 1988-08-10 |
| OA07794A (fr) | 1986-11-20 |
| IL72589A0 (en) | 1984-11-30 |
| HUT35013A (en) | 1985-05-28 |
| HU193217B (en) | 1987-08-28 |
| JPS6069022A (ja) | 1985-04-19 |
| IL72589A (en) | 1988-01-31 |
| AU564652B2 (en) | 1987-08-20 |
| ZA846151B (en) | 1985-03-27 |
| ATE36240T1 (de) | 1988-08-15 |
| CS270410B2 (en) | 1990-06-13 |
| CA1229566A (fr) | 1987-11-24 |
| NZ209171A (en) | 1988-10-28 |
| SU1487815A3 (ru) | 1989-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mchugh et al. | Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin: A new threat in burn units? | |
| CA1057195A (en) | Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use | |
| Braude et al. | Antibody to cell wall glycolipid of gram-negative bacteria: induction of immunity to bacteremia and endotoxemia | |
| CN102871996B (zh) | 一种抗菌药物组合物及其应用 | |
| SMITH et al. | Salmonella typhimurium enteritis and bacteremia in the acquired immunodeficiency syndrome | |
| Jones et al. | Prophylaxis and therapy for Pseudomonas aeruginosa infection with carbenicillin and with gentamicin. | |
| Suzuki et al. | Antiviral and interferon-inducing activities of a new peptidomannan, KS-2, extracted from culture mycelia of Lentinus edodes | |
| Walterspiel et al. | Protective effect of subinhibitory polymyxin B alone and in combination with ampicillin for overwhelming Haemophilus influenzae type B infection in the infant rat: evidence for in vivo and in vitro release of free endotoxin after ampicillin treatment | |
| Tamplin et al. | Vibrio vulnificus resists phagocytosis in the absence of serum opsonins | |
| Balachandran et al. | A study on the effect of using mangrove leaf extracts as a feed additive in the progress of bacterial infections in marine ornamental fish | |
| Beam JR | Sequestration of staphylococci at an inaccessible focus | |
| NO843274L (no) | Fremgangsmaate for fremstilling av et immunomodulatormedikament | |
| JPH05271096A (ja) | 抗菌性組成物及びそれを有効成分とする薬剤 | |
| Ribble et al. | Bacterial interference in chick embryos | |
| Deepe Jr et al. | Impairment of granulomatous inflammatory response to Histoplasma capsulatum by inhibitors of angiotensin-converting enzyme | |
| Steabben | A study on bacteriological lines of the antigens derived from Bact. dysenteriae Shiga and of their antisera in protective tests against the living organisms | |
| Sanford et al. | Oxolinic acid in the treatment of typhoid fever due to chloramphenicol-resistant strains of Salmonella typhi | |
| Marco et al. | Increased rate of survival in Streptococcus pneumoniae-infected rats treated with the new immunomodulator Pidotimod | |
| Seravalli et al. | Release of macrophage migration inhibitory factor (s) from lymphocytes stimulated by streptococcal preparations | |
| Ginsburg et al. | Once-daily cefadroxil versus twice-daily cefaclor for treatment of acute urinary tract infections in children | |
| Prado et al. | Comparative efficacy of pivmecillinam and cotrimoxazole in acute shigellosis in children | |
| SU1722502A1 (ru) | Препарат биоспорин дл профилактики и лечени желудочно-кишечных заболеваний человека | |
| Cushing | Diagnosis and treatment: antibiotic therapy of infectious diarrhea in children | |
| Jensen et al. | Alterations in Type and Bactericidal Activity of Mouse Peritoneal Phagocytes after Intraperitoneal Administration of Endotoxin | |
| Hewitt | Protection by Streptomycin, Penicillin and Licheni-formin against C. diphtheriae Infections |